Centre d'Investigations Cliniques Plurithématique, INSERM 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Université de Lorraine, Nancy, France.
Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
Clin Res Cardiol. 2021 Aug;110(8):1159-1172. doi: 10.1007/s00392-020-01794-8. Epub 2021 Jan 6.
Congestion is one of the main predictors of poor outcome in patients with heart failure (HF). Assessing and monitoring congestion is essential for optimizing HF therapy. Among the various available methods, serial measurements of estimated plasma volume (ePVS) using routine blood count and/or body weight (e.g., the Strauss, Duarte, Hakim formulas) may be useful in HF management. Further prospective study is warranted to determine whether ePVS can help optimize decongestion therapy (loop diuretics, mineralocorticoid receptor antagonists, SGLT2i) in various HF settings. This narrative review summarizes the recent evidence supporting the association of ePVS with clinical congestion and outcome(s) and discusses future directions for monitoring ePVS in HF.
充血是心力衰竭（HF）患者预后不良的主要预测因素之一。评估和监测充血对于优化 HF 治疗至关重要。在各种可用方法中，使用常规血液计数和/或体重（例如，Strauss、Duarte、Hakim 公式）估计血浆体积（ePVS）的连续测量可能对 HF 管理有用。需要进一步的前瞻性研究来确定 ePVS 是否有助于优化各种 HF 环境中的充血治疗（袢利尿剂、盐皮质激素受体拮抗剂、SGLT2i）。本综述总结了支持 ePVS 与临床充血和结局相关的最新证据，并讨论了监测 HF 中 ePVS 的未来方向。
